Herantis Pharma publishes newsletter for May-June

We shared our progress in the development of Lymfactin® with several key opinion leaders at the EURAPS 2019 meeting. Read also about our greetings from the Bio€quity meeting!

Herantis Pharma Plc
Company release 01 Jul 2019 at 7:00 am

Herantis Pharma publishes newsletter for May-June

Herantis Pharma Plc
Press release 1 July 2019 at 9:00 am

Herantis Pharma plc (“Herantis”) has published its newsletter for May-June 2019. The newsletter is also attached to this press release.

Herantis’ newsletter is published every other month on the company’s web site. It is also available by email subscription.

Further information:

Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Main media
www.herantis.com

Attachment